1. Search Result
Search Result
Results for "

CD-1/ICR mice

" in MedChemExpress (MCE) Product Catalog:

1223

Inhibitors & Agonists

13

Fluorescent Dye

12

Biochemical Assay Reagents

124

Peptides

41

Inhibitory Antibodies

170

Natural
Products

14

Recombinant Proteins

41

Isotope-Labeled Compounds

3

Antibodies

5

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19336
    BAZ2-ICR
    1 Publications Verification

    BAZ2-ICR is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds of 109 nM and 170 nM, respectively. BAZ2-ICR shows 10-15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains. BAZ2-ICR is an epigenetic chemical probe [1].
    BAZ2-<em>ICR</em>
  • HY-B0430B

    (±)-Pantothenate; (±)-Vitamin B5

    Others Neurological Disease Metabolic Disease
    (±)-Pantothenic acid ((±)-Pantothenate), a B-vitamin, is an essential vitamin required for the biosynthesis of coenzyme A (CoA) in mammalian cells. Pantothenic acid has protective activity against valproic acid (VPA)-induced neural tube defects (NTD) in CD-1 mice [1].
    (±)-Pantothenic acid
  • HY-155478

    Androgen Receptor Cancer
    Androgen receptor-IN-6 (compound 16) is an orally available androgen receptor (Androgen Receptor) potent inhibitor (IC50=0.12 μM in vitro), targeting the disordered N-terminal domain (NTD). Androgen receptor-IN-6 has good Caco2 cell membrane permeability and has an oral activity (F/%) of 16% in male CD-1 mice [1].
    Androgen receptor-IN-6
  • HY-P1302

    Opioid Receptor Neurological Disease
    Orphanin FQ(1-11), a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a Ki of 55 nM. Orphanin FQ(1-11) has no affinity for μ, δ, κ1 and κ3 receptors (Ki>1000 nM). Orphanin FQ(1-11) is analgesic in CD-1 mice [1] .
    Orphanin FQ(<em>1</em>-11)
  • HY-P1302A

    Opioid Receptor Neurological Disease
    Orphanin FQ(1-11) TFA, a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a Ki of 55 nM. Orphanin FQ(1-11) TFA has no affinity for μ, δ, κ1 and κ3 receptors (Ki>1000 nM). Orphanin FQ(1-11) TFA is analgesic in CD-1 mice [1] .
    Orphanin FQ(<em>1</em>-11) TFA
  • HY-163315

    Keap1-Nrf2 AMPK Metabolic Disease
    YPLP is a yeast-derived peptide Tyr-Pro-Leu-Pro, which exhibits activity in anti fatigue mechanisms through the nuclear factor erythroid-2-related factor 2 (Nrf2)- and AMP-activated protein kinase (AMPK) pathway. YPLP is orally active [1].
    YPLP
  • HY-146619

    Amyloid-β Serotonin Transporter Neurological Disease
    RAGE/SERT-IN-1 is a potent and orally active advanced glycation end products (RAGE) and serotonin transporter (SERT) inhibitor with IC50s of 8.26 μM and 31.09 nM, respectively. RAGE/SERT-IN-1 exhibits significant neuroprotective effect against Aβ25-35-induced neuronal damage and alleviates depressive behavior of mice. RAGE/SERT-IN-1 can be used for researching the comorbidity of Alzheimer's disease and depression [1].
    RAGE/SERT-IN-<em>1</em>
  • HY-RS02199

    Small Interfering RNA (siRNA) Others

    CD1A Human Pre-designed siRNA Set A contains three designed siRNAs for CD1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD1A Human Pre-designed siRNA Set A
    CD1A Human Pre-designed siRNA Set A
  • HY-RS02200

    Small Interfering RNA (siRNA) Others

    CD1B Human Pre-designed siRNA Set A contains three designed siRNAs for CD1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD1B Human Pre-designed siRNA Set A
    CD1B Human Pre-designed siRNA Set A
  • HY-RS02201

    Small Interfering RNA (siRNA) Others

    CD1C Human Pre-designed siRNA Set A contains three designed siRNAs for CD1C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD1C Human Pre-designed siRNA Set A
    CD1C Human Pre-designed siRNA Set A
  • HY-RS02202

    Small Interfering RNA (siRNA) Others

    CD1D Human Pre-designed siRNA Set A contains three designed siRNAs for CD1D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD1D Human Pre-designed siRNA Set A
    CD1D Human Pre-designed siRNA Set A
  • HY-RS02203

    Small Interfering RNA (siRNA) Others
    CD1E Human Pre-designed siRNA Set A contains three designed siRNAs for CD1E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CD1E Human Pre-designed siRNA Set A
    CD1E Human Pre-designed siRNA Set A
  • HY-147395

    GPR52 Neurological Disease
    GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC50 value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity [1].
    GPR52 agonist-<em>1</em>
  • HY-163345

    5-HT Receptor Neurological Disease
    5-HT7R antagonist 2 (compound 4h) is a 5-HT7R antagonist that antagonizes the G protein and β-arrestin signaling pathways, with a Ki of 67 nM, the IC50 values in cAMP and Tango tests were 2.59 μM and 39.57 μM, respectively. 5-HT7R antagonist 2 has an effect on neurogenesis and can reduce repetitive behaviors related to autism spectrum disorder (ASD) and restore neurogenesis of ASD impairment [1].
    Pharmacokinetic Analysis ICR Male Mice [1]

    药代动力学分析 [1]
    Plasma Intravenous Administration Intraperitoneal Administration
    Tmax (h) 0.08 0.25
    T1/2 (h) 0.77 1.06
    Cmax (ng/mL) 33.07 156.44
    AUClast (ng·h/mL) 28.31 143.27
    CL (L/h/kg) 41.61 -
    Vss (L/kg) 32.43 -
    MRT (h) 0.79 0.93
    F (%) 50.60
    5-HT7R antagonist 2
  • HY-106817

    LY 217896

    Influenza Virus Infection
    Amitivir (LY 217896), a thiadiazole derivative, possesses broad antiviral activity against orthomyxo- and paramyxoviruses. Amitivir is effective against influenza A and B viruses [1] .
    Amitivir
  • HY-P10027A

    Antibiotic Bacterial Infection
    Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors [1].
    Clovibactin TFA
  • HY-W012977

    DMB; Neohexanol

    TGF-beta/Smad NF-κB Endogenous Metabolite Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    3,3-Dimethyl-1-butanol (DMB) is an orally active inhibitor of trimethylamine (TMA) and trimethylamine N-oxide (TMAO). 3,3-Dimethyl-1-butanol inhibits the signaling pathway of p65 NF-κB and TGF-β1/Smad3. 3,3-Dimethyl-1-butanol has potential applications in cardiovascular disease (CVD) [1] .
    3,3-Dimethyl-<em>1</em>-butanol
  • HY-N6699

    Bacterial Parasite Apoptosis Infection Cancer
    Aflatoxin M1 is a major metabolite of Aflatoxin B1. Aflatoxin M1 is an orally active mycotoxin produced by Aspergillus flavus and Aspergillus parasiticus. The level of toxicity associated with Aflatoxin is Aflatoxin B1>Aflatoxin M1>Aflatoxin G1>Aflatoxin B2>Aflatoxin M2>Aflatoxin G2 [1] .
    Aflatoxin M<em>1</em>
  • HY-146468

    Dipeptidyl Peptidase GPR119 Potassium Channel Metabolic Disease
    DPP-4/GPR119 modulator 1 (Compound 22) is an orally active dipeptidyl peptidase IV (DPP-IV) inhibitor and GPR119 agonist. DPP-4/GPR119 modulator 1 shows blood glucose-lowering effect and moderate inhibition on hERG channel with an IC50 of 4.9 μM. DPP-4/GPR119 modulator 1 can be used for diabetes research [1] [1]. DPP-4/GPR119 modulator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    DPP-4/GPR119 modulator <em>1</em>
  • HY-137439

    VYR-006

    Antifolate Infection
    Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC50s of 1.57 and 308 nM for tgDHFR (Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis [1].
    Fanotaprim
  • HY-120872

    Others Metabolic Disease
    AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
    AJS1669 free acid
  • HY-113878

    Endogenous Metabolite Metabolic Disease
    12-OAHSA is a component of olive oil. 12-OAHSA has oral activity, and improves glucose homeostasis in insulin resistant obese mice [1].
    12-OAHSA
  • HY-P5819

    Wnt APC PROTACs β-catenin Cancer
    xStAx-VHLL is a PROTAC β-catenin degrader that manifests strong inhibition of Wnt signaling and sustains degradation of β-catenin in cancer cells and the intestinal organoids derived from wild-type and APC –/– mice. xStAx-VHLL can be used as a promising anticancer agent [1].
    xStAx-VHLL
  • HY-146615

    TAM Receptor Cancer
    Axl-IN-6 (compound 14) is an orally active and potent AXL inhibitor. Axl-IN-6 is well tolerated and significantly inhibits the tumor growth in MV-4-11 subcutaneous xenograft model [1].
    Axl-IN-6
  • HY-152031

    Amyloid-β Neurological Disease
    Glutaminyl Cyclase Inhibitor 5 (Compound 71) is a potent and selective human glutaminyl cyclase (hQC) inhibitor with an IC50 of 3.2 nM [1].
    Glutaminyl Cyclase Inhibitor 5
  • HY-153617

    Others Metabolic Disease
    FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain [1].
    FOXO<em>1</em>-IN-3
  • HY-115996

    Others Cancer
    Antitumor agent-51 possesses potent and selective inhibitory for osteosarcoma cell growth and migration with IC50 of 21.9 nM in MNNG/HOS cells. Antitumor agent-51 has a considerable bioavailability and a low toxicity [1].
    Antitumor agent-51
  • HY-158113

    Histone Acetyltransferase PROTACs Cancer
    CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC50s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) [1].
    CBPD-409
  • HY-162396

    P-glycoprotein Cancer
    P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity [1].
    P-gp inhibitor 21
  • HY-P6053

    Opioid Receptor Neurological Disease
    KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect [1].
    KK-103
  • HY-142295

    DYRK Metabolic Disease
    GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes [1].
    GNF2133
  • HY-142295A

    DYRK Metabolic Disease
    GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes [1].
    GNF2133 hydrochloride
  • HY-146715

    Microtubule/Tubulin Apoptosis Cancer
    IDO/Tubulin-IN-2 (HT2) is a potent TDO and tubulin inhibitor. IDO/Tubulin-IN-2 also shows potent activity against U87, HepG2, A549, HCT-116, and LO2 cancer cell lines, with IC50 values of 0.43, 0.036, 0.041, 0.095 and 1.04 μM, respectively. IDO/Tubulin-IN-2 remarkably promotes the antitumor activity [1].
    IDO/Tubulin-IN-2
  • HY-110197

    Others Metabolic Disease
    6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC50 value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice [1].
    6bK TFA
  • HY-139414
    Lysophosphatidylcholines
    1 Publications Verification

    Interleukin Related p38 MAPK ERK Apoptosis Inflammation/Immunology
    Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis [1] .
    Lysophosphatidylcholines
  • HY-146883A

    Filovirus Infection
    As-358 (hydrochloride) has inhibitory effects against Ebola virus and Marburg virus with IC50s of 9.1 μM and 18.1 μM, as well as exhibits good in vivo safety [1].
    As-358 hydrochloride
  • HY-147943

    PROTACs Btk Cancer
    PROTAC BTK Degrader-1 is a potent, selective and orally active PROTAC BTK degrader with an IC50 value of 34.51 nM and 64.56 nM for BTK WT and BTK-481S, respectively. PROTAC BTK Degrader-1 effectively reduces BTK protein levels and suppresses tumor growth [1]. PROTAC BTK Degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PROTAC BTK Degrader-<em>1</em>
  • HY-126383

    Others Infection Others Inflammation/Immunology Cancer
    Spilanthol is an orally active analgesic, neuroprotective, antioxidant, antimutagenic, anti-cancer, anti-inflammatory, antimicrobial and insecticidal compound.pilanthol can induce cAMP to inhibit negative regulation of urinary concentration mechanism. Spilanthol can be use as diuretic research [1] .
    Spilanthol
  • HY-P1434

    Insulin Receptor Metabolic Disease
    [Pro3]-GIP (Mouse) is a GIP receptor antagonist (IC50: 2.6 μM). [Pro3]-GIP (Mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (Mouse) can be used for research of type 2 diabetes [1] .
    [Pro3]-GIP (Mouse)
  • HY-150080

    BMS-986180

    HIV HIV Integrase Infection
    GSK3739936 (BMS-986180) is a potent HIV-1 allosteric integrase inhibitor with an IC50 value of 11.1 nM and an EC50 value of 1.7 nM. GSK3739936 is also a weak CYP inhibitor (IC50>24.3 μM). GSK3739936 shows favorable pharmacokinetic property in preclinical species with rapid absorption, low to moderate clearance and excellent oral bioavailability [1].
    GSK3739936
  • HY-120382

    Bacterial Infection
    LY 215890 ia an orally active antibacterial agent aganist Escherichia coli EC14 and Klebsiella pneumonia X26 [1].
    LY 215890
  • HY-131334

    AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect [1].
    AMPK activator 4
  • HY-163087

    Others Neurological Disease Metabolic Disease
    PT-91 is an agonist of GPR27. PT-91 exhibits high metabolic stability and brain exposure in mice [1].
    PT-91
  • HY-147548

    Others Others
    Keap1-Nrf2-IN-10 (compound 15) is a potent NQO1 inducer. Keap1-Nrf2-IN-10 inhibits oxidative stress by decreasing the levels of MDA, ROS, NQO1 in the liver for gamma-irradiated mice. Keap1-Nrf2-IN-10 improves the survival of gamma-irradiated mice [1].
    Keap<em>1</em>-Nrf2-IN-10
  • HY-143586

    CDK Cancer
    CDK7-IN-8 is a potent CDK7 inhibitor with IC50 of 54.29 nM. CDK7-IN-8 has inhibitory effect on certain cancer cells and in vivo tumor models [1].
    CDK7-IN-8
  • HY-W018723
    4-Aminobenzamidine dihydrochloride
    1 Publications Verification

    p-Aminobenzamidine dihydrochloride

    Ser/Thr Protease Cancer
    4-Aminobenzamidine (p-Aminobenzamidine) dihydrochloride is a strong trypsin inhibitor, also acting as a relatively weak urokinase type plasminogen activator (uPA) inhibitor (Ki=82 μM). 4-Aminobenzamidine can inhibit growth of a human prostate tumor in SCID mice [1] .
    4-Aminobenzamidine dihydrochloride
  • HY-143411

    HDAC Apoptosis DNA/RNA Synthesis Cancer
    GEM144 is a potent and orally active DNA polymerase α (POLA1) and HDAC 11 dual inhibitor. GEM144 induces acetylation of p53, activation of p21, G1/S cell cycle arrest, and apoptosis. GEM144 has significant antitumor activity in human orthotopic malignant pleural mesothelioma xenografts [1].
    GEM144
  • HY-155194

    Others Inflammation/Immunology
    P2X7 receptor antagonist-4 (Compound 14a) is a P2X7R antagonist. The P2X7 receptor antagonist-4 values of P2X7R IC50 in human and mouse are 64.7 and 10.1 nM, respectively. P2X7 receptor antagonist-4 can inhibit the activation of NLRP3 inflammasome, thereby inhibiting the expression of caspase-1, gasdermin D, IL-1β and IL-18 in the damaged kidney of sepsis mice [1].
    P2X7 receptor antagonist-4
  • HY-157430

    Epigenetic Reader Domain Neurological Disease
    BET-IN-21 (compound 16) is a blood-brain barrier-permeable extra terminal domain (BET) inhibitor with the Ki of 230 nM. BET-IN-21 inhibits microglia activation and has ameliorative effects on experimental autoimmune encephalomyelitis mice [1].
    BET-IN-21
  • HY-N10171

    Others Inflammation/Immunology
    GB-2a is a bioflavonoids that can be isolated from Rheedia gardneriana. GB-2a has significant analgesic activity in mice with 58.9% inhibition [1].
    GB-2a

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: